Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 803

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Cotransplantation of HLA-Identical Sibling Culture-Expanded Mesenchymal Stem Cells and Hematopoietic Stem Cells in Hematologic Malignancy Patients

Open access
Lazarus, Hillard M., Koc, Omer N., Devine, Steven M., Curtin, Peter, Maziarz, Richard T., Holland, H. Kent, Shpall, Elizabeth J., McCarthy, Philip, Atkinson, Kerry, Cooper, Brenda W., Gerson, Stanton L., Laughlin, Mary J., Loberiza, Fausto R., Moseley, Annemarie B., Bacigalupo, Andrea·2005·Biology of Blood and Marrow Transplantation
DOI 10.1016/j.bbmt.2005.02.001
Open this paper in CoChat — free account

Abstract

Mesenchymal stem cells (MSCs) are found in a variety of tissues, including human bone marrow; secrete hematopoietic cytokines; support hematopoietic progenitors in vitro; and possess potent immunosuppressive properties. We hypothesized that cotransplantation of culture-expanded MSCs and hematopoietic stem cells (HSCs) from HLA-identical sibling donors after myeloablative therapy could facilitate engraftment and lessen graft-versus-host disease (GVHD); however, the safety and feasibility of this approach needed to be established. In an open-label, multicenter trial, we coadministered culture-expanded MSCs with HLA-identical sibling-matched HSCs in hematologic malignancy patients. Patients received either bone marrow or peripheral blood stem cells as the HSC source. Patients received 1 of 4 study-specified transplant conditioning regimens and methotrexate (days 1, 3, and 6) and cyclosporine as GVHD prophylaxis. On day 0, patients were given culture-expanded MSCs intravenously (1.0-5.0 x 10(6)/kg) 4 hours before infusion of either bone marrow or peripheral blood stem cells. Forty-six patients (median age, 44.5 years; range, 19-61 years) received MSCs and HLA-matched sibling allografts. MSC infusions were well tolerated, without any infusion-related adverse events. The median times to neutrophil (absolute neutrophil count > or = 0.500 x 10(9)/L) and platelet (platelet count > or = 20 x 10(9)/L) engraftment were 14.0 days (range, 11.0-26.0 days) and 20 days (range, 15.0-36.0 days), respectively. Grade II to IV acute GVHD was observed in 13 (28%) of 46 patients. Chronic GVHD was observed in 22 (61%) of 36 patients who survived at least 90 days; it was extensive in 8 patients. Eleven patients (24%) experienced relapse at a median time to progression of 213.5 days (range, 14-688 days). The probability of patients attaining disease- or progression-free survival at 2 years after MSC infusion was 53%. Cotransplantation of HLA-identical sibling culture-expanded MSCs with an HLA-identical sibling HSC transplant is feasible and seems to be safe, without immediate infusional or late MSC-associated toxicities. The optimal MSC dose and frequency of administration to prevent or treat GVHD during allogeneic HSC transplantation should be evaluated further in phase II clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.bbmt.2005.02.001

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 61

  1. Armitage, 1994, Bone marrow transplantation, N Engl J Med., 330, 827, 10.1056/NEJM199403243301206 · DOI · Paper page
  2. Tabbara, 2002, Allogeneic hematopoietic stem cell transplantation, Arch Intern Med., 162, 1558, 10.1001/archinte.162.14.1558 · DOI
  3. Caplan, 1991, Mesenchymal stem cells, J Orthop Res., 9, 641, 10.1002/jor.1100090504 · DOI · Paper page
  4. Deans, 2000, Mesenchymal stem cells, Exp Hematol., 28, 875, 10.1016/S0301-472X(00)00482-3 · DOI · Paper page
  5. Haynesworth, 1996, Cytokine expression by human marrow derived mesenchymal progenitor cells in vitro, J Cell Physiol., 166, 585, 10.1002/(SICI)1097-4652(199603)166:3<585::AID-JCP13>3.0.CO;2-6 · DOI · Paper page
  6. Majumdar, 1998, Phenotypic and functional comparison of cultures of marrow-derived mesenchymal stem cells (MSCs) and stromal cells, J Cell Physiol., 176, 186, 10.1002/(SICI)1097-4652(199807)176:1<57::AID-JCP7>3.0.CO;2-7 · DOI · Paper page
  7. Almeida-Porada, 1999, Cotransplantation of stroma results in enrichment of engraftment and early expression of donor hematopoietic stem cells in utero, Exp Hematol., 27, 1569, 10.1016/S0301-472X(99)00090-9 · doi:10.1016/s0301-472x(99)00090-9
  8. Klyushnenkova, 1998, Human mesenchymal stem cells suppress allogeneic T cell responses in vitro, Blood, 92, 642a
  9. McIntosh, 1999, Suppression of alloreactive T cell responses by human mesenchymal stem cells involves CD8+ cells, Blood, 94, 133a
  10. Bartholomew, 2002, Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo, Exp Hematol., 30, 42, 10.1016/S0301-472X(01)00769-X · DOI · Paper page
  11. Di Nicola, 2002, Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli, Blood, 99, 3838, 10.1182/blood.V99.10.3838 · DOI · Paper page
  12. McMannus, 1984, Busulfan-induced chronic bone marrow failure, Blood, 64, 1036, 10.1182/blood.V64.5.1036.1036 · DOI
  13. Uhlman, 1991, BCNU treatment of marrow stromal monolayers reversibly alters haematopoiesis, Br J Haematol., 78, 3304, 10.1111/j.1365-2141.1991.tb04441.x · DOI
  14. Domenech, 1994, Haemopoiesis of transplanted patients with autologous marrows assessed by long-term marrow culture, Br J Haematol., 88, 488, 10.1111/j.1365-2141.1994.tb05064.x · DOI
  15. O’Flaherty, 1995, Bone marrow stromal function from patients after bone marrow transplantation, Bone Marrow Transplant., 15, 207
  16. Simmons, 1987, Host origin of marrow stromal cells following allogeneic bone marrow transplantation, Nature, 328, 429, 10.1038/328429a0 · DOI · Paper page
  17. Koc, 1999, Bone marrow-derived mesenchymal stem cells remain host-derived despite successful hematopoietic engraftment after allogeneic transplantation in patients with lysosomal and peroxisomal storage diseases, Exp Hematol., 27, 1675, 10.1016/S0301-472X(99)00101-0 · DOI · Paper page
  18. Agematsu, 1991, Recipient origin of bone marrow-derived fibroblastic stromal cells during all periods following bone marrow transplantation in humans, Br J Haematol., 79, 359, 10.1111/j.1365-2141.1991.tb08041.x · DOI
  19. Stute, 2002, Human mesenchymal stem cells are not of donor origin in patients with severe aplastic anemia who underwent sex-mismatched allogeneic bone marrow transplant, J Hematother Stem Cell Res., 11, 977, 10.1089/152581602321080646 · doi:10.1089/152581602321080646
  20. Keating, 1982, Donor origin of the in vitro haematopoietic microenvironment after marrow transplantation in man, Nature, 298, 280, 10.1038/298280a0 · DOI
  21. Lazarus, 1995, Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells) [MPCs], Bone Marrow Transplant., 16, 557
  22. Koç, 2000, Rapid hematopoietic recovery after co-infusion of autologous culture-expanded human mesenchymal stem cells (hMSCs) and PBPCs in breast cancer patients receiving high dose chemotherapy, J Clin Oncol., 18, 307, 10.1200/JCO.2000.18.2.307 · DOI · Paper page
  23. Lennon, 1996, Development of a serum screen for mesenchymal progenitor cells from bone marrow, In Vitro Cell Dev Biol., 32, 602, 10.1007/BF02724045 · DOI · Paper page
  24. Mickelson, 1993, A comparative study of HLA-DRB1 typing by standard serology and hybridization of non-radioactive sequence-specific oligonucleotide probes to PCR-amplified DNA, Tissue Antigens, 41, 86, 10.1111/j.1399-0039.1993.tb01984.x · DOI
  25. Petersdorf, 1991, Ten HLA-DR4 alleles defined by sequence polymorphisms within the DRB1 first domain, Immunogenetics, 33, 267, 10.1007/BF00230505 · DOI
  26. Copelan, 1993, Allogeneic bone marrow transplantation for acute myelogenous leukemia, acute lymphocytic leukemia, and multiple myeloma following preparation with busulfan and cyclophosphamide (BuCy2), Semin Oncol., 20, 33
  27. Socié, 2001, Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia, Blood, 98, 3569, 10.1182/blood.V98.13.3569 · doi:10.1182/blood.v98.13.3569
  28. Clift, 1994, Marrow transplantation for chronic myeloid leukemia, Blood, 84, 2036, 10.1182/blood.V84.6.2036.2036 · DOI · Paper page
  29. Mills, 1995, BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin’s lymphoma, J Clin Oncol., 13, 588, 10.1200/JCO.1995.13.3.588 · doi:10.1200/jco.1995.13.3.588
  30. Blume, 1993, A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission, Blood, 81, 2187, 10.1182/blood.V81.8.2187.2187 · doi:10.1182/blood.v81.8.2187.2187
  31. Bacigalupo, 1999, Early predictors of transplant-related mortality (TRM) after allogeneic bone marrow transplants (BMT), Bone Marrow Transplant., 24, 653, 10.1038/sj.bmt.1701953 · doi:10.1038/sj.bmt.1701953
  32. Storb, 1986, Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia, N Engl J Med., 314, 729, 10.1056/NEJM198603203141201 · DOI · Paper page
  33. Sullivan, 1981, Chronic graft-versus-host disease in 52 patients, Blood, 57, 267, 10.1182/blood.V57.2.267.267 · doi:10.1182/blood.v57.2.267.267
  34. Atkinson, 1989, Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease, Bone Marrow Transplant., 4, 247
  35. Bowden, 1991, Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant, Blood, 78, 246, 10.1182/blood.V78.1.246.246 · doi:10.1182/blood.v78.1.246.246
  36. Sokos, 2002, Intravenous immunoglobulin (IVIG), Biol Blood Marrow Transplant., 8, 117, 10.1053/bbmt.2002.v8.pm11939601 · DOI
  37. Goodrich, 1993, Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant, Ann Intern Med., 118, 173, 10.7326/0003-4819-118-3-199302010-00003 · DOI · Paper page
  38. Vigorito, 1998, A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies, Bone Marrow Transplant., 22, 1145, 10.1038/sj.bmt.1701510 · doi:10.1038/sj.bmt.1701510
  39. Schmitz, 1998, Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia, Bone Marrow Transplant., 21, 995, 10.1038/sj.bmt.1701234 · doi:10.1038/sj.bmt.1701234
  40. Blaise, 2000, Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia, J Clin Oncol., 18, 537, 10.1200/JCO.2000.18.3.537 · doi:10.1200/jco.2000.18.3.537
  41. Powles, 2000, Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases, Lancet, 355, 1231, 10.1016/S0140-6736(00)02090-0 · DOI · Paper page
  42. Bensinger, 2001, Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers, N Engl J Med., 344, 175, 10.1056/NEJM200101183440303 · DOI · Paper page
  43. Russell, 1999, Allogeneic blood stem cell and bone marrow transplantation for acute myelogenous leukemia and myelodysplasia, Bone Marrow Transplant., 24, 1177, 10.1038/sj.bmt.1702051 · doi:10.1038/sj.bmt.1702051
  44. Champlin, 2000, Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation, Blood, 95, 3702
  45. Couban, 2002, A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies, Blood, 100, 1525, 10.1182/blood-2002-01-0048 · DOI · Paper page
  46. Solano, 1998, Chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell or bone marrow transplantation from matched related donors. A case-control study. Spanish Group of Allo-PBT, Bone Marrow Transplant., 22, 1129, 10.1038/sj.bmt.1701500 · doi:10.1038/sj.bmt.1701500
  47. Heldal, 2000, A randomised study of allogeneic transplantation with stem cells from blood or bone marrow, Bone Marrow Transplant., 25, 1129, 10.1038/sj.bmt.1702422 · doi:10.1038/sj.bmt.1702422
  48. Lazarus, 2001, Culture-expanded human marrow-derived MSCs in clinical hematopoietic stem cell transplantation, Graft, 3, 329
  49. Koc, 2001, Mesenchymal stem cells, Bone Marrow Transplant., 27, 235, 10.1038/sj.bmt.1702791 · DOI · Paper page
  50. Nash, 1992, Acute graft-versus-host disease, Blood, 80, 1838, 10.1182/blood.V80.7.1838.1838 · DOI · Paper page
  51. Kumar, 2002, Omission of day +11 methotrexate for graft-versus-host disease prophylaxis after allogeneic BMT increases the risk of severe acute graft-versus-host disease, Bone Marrow Transplant., 30, 161, 10.1038/sj.bmt.1703616 · doi:10.1038/sj.bmt.1703616
  52. Mohty, 2002, Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC). Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study, Blood, 100, 3128, 10.1182/blood.V100.9.3128 · doi:10.1182/blood.v100.9.3128
  53. Rasmusson, 2003, Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells, Transplantation, 76, 1208, 10.1097/01.TP.0000082540.43730.80 · DOI · Paper page
  54. Krampera, 2003, Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide, Blood, 101, 3722, 10.1182/blood-2002-07-2104 · DOI · Paper page
  55. Majumdar, 2003, Characterization and functionality of cell surface molecules on human mesenchymal stem cells, J Biomed Sci., 10, 228, 10.1007/BF02256058 · DOI · Paper page
  56. Tse, 2003, Suppression of allogeneic T-cell proliferation by human marrow stromal cells, Transplantation, 75, 389, 10.1097/01.TP.0000045055.63901.A9 · DOI · Paper page
  57. Maitra, 2004, Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation, Bone Marrow Transplant., 33, 597, 10.1038/sj.bmt.1704400 · DOI · Paper page
  58. Le Blanc, 2004, Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells, Lancet, 363, 1439, 10.1016/S0140-6736(04)16104-7 · DOI · Paper page
  59. Le Blanc, 2003, Immunomodulatory effects of fetal and adult mesenchymal stem cells, Cytotherapy, 5, 485, 10.1080/14653240310003611 · DOI · Paper page
  60. Dalton, 2004, Targeting the bone marrow microenvironment in hematologic malignancies, Semin Hematol., 41, 1, 10.1053/j.seminhematol.2004.02.001 · DOI
  61. Konopleva, 2002, Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins, Leukemia, 16, 1713, 10.1038/sj.leu.2402608 · DOI · Paper page

Cited by

See all 803

Metadata

Authors
Lazarus, H. M., Koc, O. N., Devine, S. M., Curtin, P., Maziarz, R. T., Holland, H. K., Shpall, E. J., McCarthy, P., Atkinson, K., Cooper, B. W., Gerson, S. L., Laughlin, M. J., Loberiza, F. R., Moseley, A. B., & Bacigalupo, A.
Venue
Biology of Blood and Marrow Transplantation
Publisher
Elsevier BV
Published
2005-05
Volume
11
Issue
5
Pages
389-398
ISSN
1083-8791 (ISSN-L)
DOI
10.1016/j.bbmt.2005.02.001
OpenAlex
W2100764718
Cited by
803
References
2
FWCI
34.27
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cotransplantation of HLA-Identical Sibling Culture-Expanded Mesenchymal Stem Cells and Hematopoietic Stem Cells in Hematologic Malignancy Patients. https://app.cochat.ai/papers/10.1016/j.bbmt.2005.02.001
The paper
Lazarus, H. M., Koc, O. N., Devine, S. M., Curtin, P., Maziarz, R. T., Holland, H. K., Shpall, E. J., McCarthy, P., Atkinson, K., Cooper, B. W., Gerson, S. L., Laughlin, M. J., Loberiza, F. R., Moseley, A. B., & Bacigalupo, A. (2005). Cotransplantation of HLA-Identical Sibling Culture-Expanded Mesenchymal Stem Cells and Hematopoietic Stem Cells in Hematologic Malignancy Patients. Biology of Blood and Marrow Transplantation. https://doi.org/10.1016/j.bbmt.2005.02.001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.